JP2016094424A5 - - Google Patents

Download PDF

Info

Publication number
JP2016094424A5
JP2016094424A5 JP2015229465A JP2015229465A JP2016094424A5 JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5 JP 2015229465 A JP2015229465 A JP 2015229465A JP 2015229465 A JP2015229465 A JP 2015229465A JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015229465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016094424A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016094424A publication Critical patent/JP2016094424A/ja
Publication of JP2016094424A5 publication Critical patent/JP2016094424A5/ja
Pending legal-status Critical Current

Links

JP2015229465A 2009-10-14 2015-11-25 EphA3に対する抗体 Pending JP2016094424A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
US61/251,668 2009-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012534368A Division JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Publications (2)

Publication Number Publication Date
JP2016094424A JP2016094424A (ja) 2016-05-26
JP2016094424A5 true JP2016094424A5 (enExample) 2016-10-06

Family

ID=43499991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体
JP2015229465A Pending JP2016094424A (ja) 2009-10-14 2015-11-25 EphA3に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Country Status (11)

Country Link
US (2) US8664365B2 (enExample)
EP (1) EP2488554B1 (enExample)
JP (2) JP2013508292A (enExample)
CN (1) CN102666589B (enExample)
AU (1) AU2010313621C1 (enExample)
CA (1) CA2777068C (enExample)
DK (1) DK2488554T3 (enExample)
ES (1) ES2743558T3 (enExample)
PL (1) PL2488554T3 (enExample)
PT (1) PT2488554T (enExample)
WO (1) WO2011053465A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011235867B2 (en) * 2010-04-01 2015-12-03 Kalobios Pharmaceuticals, Inc. EphA3 antibodies for the treatment of multiple myeloma
JP2013537403A (ja) * 2010-06-18 2013-10-03 カロバイオス ファーマシューティカルズ インコーポレイティッド 固形腫瘍の存在のマーカーとしてのEphA3の検出
US9109032B2 (en) 2011-08-12 2015-08-18 Kalobios Pharmaceuticals, Inc. Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
PL3708583T3 (pl) 2013-08-01 2022-06-06 Five Prime Therapeutics, Inc. Afukozylowane przeciwciała anty-fgfr2iiib
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるfgfr2阻害剤単独または免疫刺激剤との組み合わせ
US20190270821A1 (en) * 2016-09-13 2019-09-05 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
JP7299842B2 (ja) 2017-05-16 2023-06-28 ファイヴ プライム セラピューティクス インク がん治療における化学療法剤と組み合わせた抗fgfr2抗体
WO2019165982A1 (en) * 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
WO2021068040A1 (en) * 2019-10-09 2021-04-15 The Council Of The Queensland Institute Of Medical Research Targeting epha3 and uses thereof
TW202134278A (zh) 2019-11-08 2021-09-16 美商胡曼尼根公司 用於治療腫瘤之epha3導向car-t細胞
US20240025971A1 (en) * 2020-10-23 2024-01-25 Atreca, Inc. Antibodies to coronavirus sars-cov-2
JP7726496B2 (ja) * 2021-08-06 2025-08-20 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 新規な抗EphA2キメラ抗原受容体及びそれを発現する免疫細胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1993000425A1 (en) 1991-06-21 1993-01-07 Amrad Corporation Limited A novel receptor-type tyrosine kinase and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003078637A2 (en) 2002-03-19 2003-09-25 Plant Research International B.V. Optimizing glycan processing in plants
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7981843B2 (en) * 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
CA2577329A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2006055778A2 (en) 2004-11-16 2006-05-26 Kalobios, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
CA2679986C (en) 2007-03-08 2018-03-06 Martin Lackmann Epha3 antibodies for the treatment of solid tumors
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
CN102405237A (zh) * 2009-03-06 2012-04-04 卡罗拜奥斯制药公司 利用EphA3抗体治疗白血病和慢性骨髓增生性疾病

Similar Documents

Publication Publication Date Title
JP2016094424A5 (enExample)
JP2013508292A5 (enExample)
JP2016536361A5 (enExample)
JP2015534579A5 (enExample)
JP2018506277A5 (enExample)
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
JP2018534933A5 (enExample)
JP2017535257A5 (enExample)
JP2017507652A5 (enExample)
JP2017529838A5 (enExample)
JP2011514150A5 (enExample)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2015503909A5 (enExample)
JP2020536109A5 (enExample)
JP2014511179A5 (enExample)
JP2016188209A5 (enExample)
JP2017515815A5 (enExample)
JP2009521496A5 (enExample)
JP2014158469A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2011506483A5 (enExample)
JP2018529661A5 (enExample)
JP2018512402A5 (enExample)